Thomas Holm Pedersen on LinkedIn: Happy to share that NMD was awarded the Startup of the Year 2022 at Aarhus…
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
Stor pariserfond investerer i dansk biotekselskab: Scorer over 250 mio. kr. for anden gang
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
NMD Pharma (@NMDPharma) / Twitter
NMD Pharma Raises €35 Million in a new Financing
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma - PIR International
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
Management team — NMD Pharma
NMD Pharma Raises €35M Financing - FinSMEs
Other news — News — NMD Pharma
NMD Pharma expands its US presence — NMD Pharma
NMD Pharma - PIR International
NMD PHARMA APS innovation strategy - GoodIP
NMD Pharma Raises €35 Million in a new Financing — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Management team — NMD Pharma
NMD Pharma cleared for spinal muscular atrophy trial
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma (@NMDPharma) / Twitter
NMD Pharma receives Orphan Drug Designation from FDA for NMD670 for the Treatment of Myasthenia Gravis | BioSpace
